Roxana Uri Miranda-Labra

Roxana Uri Miranda-Labra

Auto-generated profile, based on publicly available information

Roxana Uri Miranda-Labra

Experimental and Translational Medicine, Health Sciences Department, Universidad Autónoma Metropolitana-Iztapalapa, Mexico City 09340, Mexico

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2022
Verified
Journal Article
Open access
PDF file
AEAlejandro Escobedo-Calvario
Alejandro Escobedo-Calvario
LCLisette Chavez-Rodríguez
Lisette Chavez-Rodríguez
ASArturo Simoni
Arturo Simoni
VSVerónica Souza-Arroyo
Verónica Souza-Arroyo
RMRoxana U. Miranda-Labra
Roxana U. Miranda-Labra
MGMaría Concepción Gutierrez-Ruiz
María Concepción Gutierrez-Ruiz
Hepatocellular carcinoma (HCC) is considered one of the most aggressive tumors worldwide. The consumption of lipid-enriched diets, mainly high cholesterol, induces oxidative stress and chronic inflammation, leading to HCC progression. Moreover, fatty acids and cholesterol could display differential responses on immune cells inside the tumor immune microenvironment (TIME). Tumor-associated macrophages (TAMs) represent one of the most critical leukocytes in the tumor microenvironment (TME) displaying pro-tumoral responses and one of the mainly cholesterol donors to cancer cells. Immunotherapy or cholesterol regulators, alone or combined, would represent an effective strategy for HCC treatment. Nonetheless, steatotic etiology from non-alcoholic fatty liver disease (NAFLD)-HCC tumors has been unexpectedly resulting in highly aggressive behavior.

5 August 2025
Verified
Journal Article
Open access
PDF file
LRLuis A. Rodríguez-Rojas
Luis A. Rodríguez-Rojas
LBLeticia Bucio-Ortiz
Leticia Bucio-Ortiz
VSVerónica Souza-Arroyo
Verónica Souza-Arroyo
MGMaría Concepción Gutierrez-Ruiz
María Concepción Gutierrez-Ruiz
Luis Gomez-QuirozLuis Gomez-Quiroz
Luis Gomez-Quiroz
RMRoxana U. Miranda-Labra
Roxana U. Miranda-Labra
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease worldwide. Its prevalence is increasing due to its close relationship with obesity, insulin resistance, and other metabolic disorders. In this context, the gut-liver axis has been identified as a fundamental regulator in the progression of MASLD, integrating metabolic, immunological, and inflammatory signals that influence hepatic homeostasis. This article reviews the interconnection between the intestine and the liver in the onset and progression of MASLD, highlighting the roles of cholesterol and its metabolism, intestinal barrier permeability, microbiota, and hepatic signaling pathways. We analyze how intestinal dysbiosis and alterations in the enterohepatic circulation of bile acids affect cholesterol absorption and metabolism. Furthermore, we address the influence of endotoxin translocation, activation of the innate immune system, and the interaction of key transcription factors on disease progression from steatosis to advanced fibrosis and hepatocellular carcinoma (HCC). Finally, therapeutic strategies, including pharmacological, dietary, and immunomodulation-based approaches, are discussed to regulate cholesterol metabolism, modulate the intestinal microbiota, and restore gut-liver axis homeostasis. Integrating this knowledge could open new perspectives for treating and preventing MASLD, addressing the disease from a broader and multidisciplinary viewpoint.

23 January 2023 in Applied Microbiology and Biotechnology
Verified
Journal Article
Closed access
PDF file
APAiled Pérez-Sánchez
Ailed Pérez-Sánchez
AMArmando Mejía
Armando Mejía
RMRoxana Uri Miranda-Labra
Roxana Uri Miranda-Labra
JBJavier Barrios-González
Javier Barrios-González

11 August 2022
Verified
Journal Article
Open access
PDF file
JLJocelyn López-Ramirez
Jocelyn López-Ramirez
RLRoberto Lazzarini
Roberto Lazzarini
MGMonserrat Gerardo-Ramírez
Monserrat Gerardo-Ramírez
AEAlejandro Escobedo-Calvario
Alejandro Escobedo-Calvario
LCLisette Chavez-Rodríguez
Lisette Chavez-Rodríguez
LBLeticia Bucio-Ortiz
Leticia Bucio-Ortiz
Aim: Cholestasis remains a partially characterized disease. Evidence has been gained that it is a systemic disease that begins in the liver but significantly impacts other organs and systems such as the kidney, heart, and intestine, among others. One of the primary damage mechanisms is the generation of reactive oxygen species (ROS), which eventually leads to oxidative stress, impacting canalicular morphology and actin cytoskeleton changes that could worsen the problem. These characteristics are also observed in the kidney and intestine. The work focused on addressing the intestine effects of intrahepatic cholestasis induced by α-naphthyl isothiocyanate (ANIT) and the protective response of the hepatocyte growth factor (HGF). Methods: The 10- to 12-week-old CD1 male mice were treated with ANIT and then treated or not with HGF; intestine damage was addressed by histology, immunohistochemistry (IHC) of specific markers, oxidative stress, and apoptosis. Results: Results show changes in the intestine histology, particularly the colon and ileum, induced by the cholestasis. HGF treatment restored the histology presentation and reverted the oxidative damage, clearly indicating a healing response. This observation was supported by an increment in anti-inflammatory macrophages (CD163+) in the HGF treatment. Conclusions: The data prove that HGF induces a protective and repairing response in the intestine under cholestatic challenges.

30 December 2025 in Exploration of digestive diseases
Verified
Journal Article
Open access
PDF file
NGNatanael German-Ramirez
Natanael German-Ramirez
MGMonserrat Gerardo-Ramírez
Monserrat Gerardo-Ramírez
GDGuadalupe I. DomínGuez-GómEz
Guadalupe I. DomínGuez-GómEz
FMFelipe Masso
Felipe Masso
APAraceli Paez-Arenas
Araceli Paez-Arenas
Luis Gomez-QuirozLuis Gomez-Quiroz
Luis Gomez-Quiroz
Aim: Hepatocellular carcinoma (HCC) accounts for 90% of liver tumors and is the fourth leading cause of cancer-related deaths worldwide. Current treatments have poor outcomes for HCC, highlighting the urgent need for new and effective therapies. Growth differentiation factor 11 (GDF11), a member of the TGF-β superfamily, regulates differentiation, proliferation, and migration processes, effects observed in cancer, including HCC. In this study, we aimed to investigate the chemosensitizing effects on human liver cancer cells. Methods: We pre-treated Huh7 and Hep3B cells with GDF11 50 ng/mL for 72 h in the presence of sorafenib (Sfb) or cisplatin (CDDP) and evaluated cellular response. Results: Pre-treatment with GDF11 lowered the IC50 of CDDP and Sfb in Huh7 cells. Similar effects were observed in Hep3B cells. Additionally, combining GDF11 with CDDP or Sfb significantly reduced cell viability and decreased the size and number of spheroids. Furthermore, we found that the chemosensitizing effect is initiated by GDF11 binding to the type I receptor ALK5. Inhibition of ALK5 abolished SMAD2 activation, impacting the chemosensitizing effects. Finally, GDF11, combined with Sfb or CDDP, reduced the activity of drug transporters MRP2, MRP3, and MRP4, which explains its chemosensitizing properties. Conclusions: GDF11 increases the sensitivity of HCC-derived cell lines to Sfb and CDDP by modulating the drug-efflux transporters MRP2, MRP3, and MRP4.